Regeneron Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $33,080 Mil.
During the past 12 months, Regeneron Pharmaceuticals's average Total Assets Growth Rate was 3.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 17.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 21.40% per year.
During the past 10 years, the average Total Assets Growth Rate was 26.60% per year.
During the past 13 years, Regeneron Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 207.90%. The lowest was -13.40%. And the median was 25.10%.
Total Assets is connected with ROA %. Regeneron Pharmaceuticals's annualizedROA % for the quarter that ended in Dec. 2023 was 14.22%. Total Assets is also linked to Revenue through Asset Turnover. Regeneron Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.11.
Regeneron Pharmaceuticals Total Assets Historical Data
The historical data trend for Regeneron Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Regeneron Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
14,805.20
17,163.30
25,434.80
29,214.50
33,080.20
Regeneron Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
29,214.50
30,059.90
30,657.50
32,163.30
33,080.20
Regeneron Pharmaceuticals Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Regeneron Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regeneron Pharmaceuticals (NAS:REGN) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Regeneron Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Regeneron Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REGN has been successfully added to your 